Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $28.6875.

ROIV has been the subject of several research reports. Citigroup lifted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. HC Wainwright upped their target price on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Guggenheim raised their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, The Goldman Sachs Group raised their target price on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th.

Insider Activity

In other Roivant Sciences news, insider Frank Torti sold 587,390 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the completion of the sale, the insider owned 13,736,547 shares in the company, valued at approximately $377,892,407.97. This trade represents a 4.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mayukh Sukhatme sold 339,441 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $26.47, for a total value of $8,985,003.27. Following the completion of the transaction, the insider owned 19,148,664 shares in the company, valued at $506,865,136.08. The trade was a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 13,318,014 shares of company stock worth $315,727,023. 10.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. Dorsey Wright & Associates bought a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $8,162,000. Invesco Ltd. lifted its stake in Roivant Sciences by 28.9% in the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock worth $49,508,000 after purchasing an additional 512,129 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Roivant Sciences in the 4th quarter valued at $227,000. Empowered Funds LLC purchased a new position in shares of Roivant Sciences during the 4th quarter valued at $396,000. Finally, VestGen Investment Management bought a new position in Roivant Sciences in the 4th quarter worth about $743,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $27.76 on Tuesday. Roivant Sciences has a one year low of $8.73 and a one year high of $27.94. The business has a 50-day simple moving average of $23.44 and a 200 day simple moving average of $19.07. The firm has a market capitalization of $19.87 billion, a price-to-earnings ratio of -23.73 and a beta of 1.22.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.